Company news

Incyte Corporation news in 2026

Incyte Corporation's news releases, calls and decks from 2026, newest first.

View company

2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute

November 6, 2026

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026

November 4, 2026

Incyte to Present at Upcoming Investor Conferences

November 4, 2026

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

October 29, 2026

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

October 26, 2026

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

October 24, 2026

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

October 24, 2026

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

October 18, 2026

Incyte to Report Third Quarter Financial Results

October 8, 2026

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

September 22, 2026

Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program

September 10, 2026

Incyte - Opzelura Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

July 30, 2026

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

July 29, 2026

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

July 28, 2026

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

July 17, 2026

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

July 13, 2026

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

July 6, 2026

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

June 26, 2026

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

June 19, 2026

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

June 13, 2026

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

June 13, 2026

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

June 13, 2026

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

June 8, 2026

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

May 29, 2026

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

May 20, 2026

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

May 18, 2026

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

May 12, 2026

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

May 7, 2026

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

May 1, 2026

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

April 28, 2026

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 27, 2026

Incyte Announces Executive Leadership Appointments

March 24, 2026

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 19, 2026

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

March 5, 2026

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

February 26, 2026

Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

February 10, 2026

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

January 29, 2026

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results

January 26, 2026

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma

January 4, 2026

Calls in 2026

Decks in 2026